Stem Cell Therapeutics Corp receives permission from Health Canada for first ever brain injury trial
Stem Cell Therapeutics Corp today announced to have received the No Objection Letter from the Health Canada to study the Chorionic Gonadotropin (hCG) & Erythropoietin (EPO) in severe traumatic brain injury (TBI). It is the first study of its kind in Canada.
The protocol of the Phase IIa TBI study has been reviewed by Health Canada. It has been approved by the University of Calgary’s Office of Medical Bioethics.
To describe, the traumatic injury to the head resulting from automobile accidents, concussive explosions or serious athletic impact to the head represents serious events that cause loss of independence and demand intense medical intervention with recovery periods that often persist for months or years. A therapy that induces improved neurological recovery or functional recovery after an acute injury would increase patient independence, decrease rehabilitation time and cost, represent a new important scientific advancement and medical development.
NTx(TM)-265 for Traumatic Brain Injury: The NTx(TM)-265 regimen is similar to that used in the REGENESIS Phase IIb stroke program. The objectives of the regimen are to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the severe brain injury, and importantly, to direct functional recovery of motor, visual and cognitive capacity.
About the About Stem Cell Therapeutics Corp: it is Canadian public biotechnology company. It focuses on the development and commercialization of drug-based therapies to treat central nervous system diseases.